The constant growth of public health expenditure is mainly due to population aging, scientific and technological innovation, increasing demand for health. Adverse drug reactions (ADRs) lower patients quality of life and increase costs of care, mainly in hospitals. Active pharmacovigilance projects - as already being implemented in the USA - may contribute to cut such avoidable costs. The present project innovation consists in employing pharmacovigilance as an additional tool to reduce health expenditure, in a collaborative way. It is therefore necessary - also in our country - to join resources and competencies at various levels (local, regional, national) to reach the common target of public health protection. Our project considers 4 phases: fact-finding, engagement of 8 hospital wards in Verona, expansion at regional level, national expansion. The “Facilitating Monitor” should be the specific professional figure - funded by the hospital administration - dedicated to pharmacovigilance at the hospital wards, to monitor and therefore prevent/decrease ADRs, reducing the resulting length of stay. Prof. Minuz conducted a pivotal study to estimate the number of ADRs due to medication errors, their causes, the preventability of the ADRs and the consequent lengths of stay. We used the raw data coming from the study to calculate the costs for 229 in-patients who reported at least one ADR during a 146 days observation period. The total avoidable cost, due to the increased length of stay for in-patients who experienced at least one preventable ADR, was € 212,700 i.e. 8% of the hospitalization cost for in-patients who experienced an ADR and 2% of the total cost of hospitalization. The results were extrapolated to obtain the total annual saving in Verona university hospitals, which could be around € 8-9 millions.
Il Monitor Facilitatore: ruolo attivo nella clinical governance e nella creazione di una cultura di farmacovigilanza, intesa come strumento per la tutela della salute pubblica e strategia di razionalizzazione della spesa ospedaliera .
Magro, Lara
2014-01-01
Abstract
The constant growth of public health expenditure is mainly due to population aging, scientific and technological innovation, increasing demand for health. Adverse drug reactions (ADRs) lower patients quality of life and increase costs of care, mainly in hospitals. Active pharmacovigilance projects - as already being implemented in the USA - may contribute to cut such avoidable costs. The present project innovation consists in employing pharmacovigilance as an additional tool to reduce health expenditure, in a collaborative way. It is therefore necessary - also in our country - to join resources and competencies at various levels (local, regional, national) to reach the common target of public health protection. Our project considers 4 phases: fact-finding, engagement of 8 hospital wards in Verona, expansion at regional level, national expansion. The “Facilitating Monitor” should be the specific professional figure - funded by the hospital administration - dedicated to pharmacovigilance at the hospital wards, to monitor and therefore prevent/decrease ADRs, reducing the resulting length of stay. Prof. Minuz conducted a pivotal study to estimate the number of ADRs due to medication errors, their causes, the preventability of the ADRs and the consequent lengths of stay. We used the raw data coming from the study to calculate the costs for 229 in-patients who reported at least one ADR during a 146 days observation period. The total avoidable cost, due to the increased length of stay for in-patients who experienced at least one preventable ADR, was € 212,700 i.e. 8% of the hospitalization cost for in-patients who experienced an ADR and 2% of the total cost of hospitalization. The results were extrapolated to obtain the total annual saving in Verona university hospitals, which could be around € 8-9 millions.
| File | Dimensione | Formato | |
|---|---|---|---|
|
GIFF1_2014_23_56.pdf
accesso aperto
Tipologia:
Altro materiale allegato
Licenza:
Dominio pubblico
Dimensione
9.47 MB
Formato
Adobe PDF
|
9.47 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
